BioCentury | Jun 5, 2020
Emerging Company Profile

Epsilogen: co-opting IgE antibodies against cancer

Epsilogen is taking a long overlooked isotype of human antibodies -- the IgE class -- and leveraging their high affinity for immune effector cells to seek out and destroy solid tumors. “What we are doing...
BioCentury | Aug 20, 2018
Preclinical News

Malaria protein helps detect circulating tumor cells

VarCT Diagnostics ApS is developing a cancer diagnostic that employs a malaria protein to target circulating tumor cells based on research from University of Copenhagen and colleagues. The academic team previously showed that the recombinant...
BioCentury | Apr 20, 2018
Clinical News

Symic's SB-061 misses in Phase II for OA of the knee

...OA patients with knee effusions this year. The candidate is a mimic of the proteoglycan aggrecan...
...Inc., Emeryville, Calif. Product: SB-061 Business: Autoimmune Molecular target: NA Description: Mimic of the proteoglycan aggrecan...
BioCentury | Apr 3, 2018
Distillery Therapeutics

Cancer

INDICATION: Brain cancer Patient sample, cell culture and mouse studies suggest CAR T cells targeting MCSP could help treat glioblastoma. In tumor samples from patients, high MCSP expression was correlated with poor overall survival. In...
BioCentury | Mar 29, 2018
Translation in Brief

Putting GBM in Check

A new target added to the mix of glioblastoma CAR T antigens, MCSP, checks all of the boxes of a good cell therapy for solid tumors, according to a study in Science Translational Medicine . Identifying...
BioCentury | Feb 28, 2018
Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers Detection of a panel of circulating tumor cell (CTC)-derived RNA transcripts in blood could help predict survival and disease progression in metastatic melanoma patients receiving immune checkpoint inhibitors. The method scores blood...
BioCentury | May 23, 2017
Financial News

Symic Bio raises $30M in series B

...begin a Phase II study next half of SB-061 , a mimic of the proteoglycan aggrecan...
BioCentury | Nov 17, 2016
Clinical News

SB-061: Completed Ph I/IIa enrollment

...Calif. Product: SB-061 , SB061 Business: Autoimmune Molecular target: NA Description: Mimic of the proteoglycan aggrecan...
BioCentury | Aug 15, 2016
Finance

Serving returns

...assets are SB-030 , a mimic of Decorin , and SB-061 , a mimic of aggrecan...
...Inc. First-in-class artificial proteoglycan mimetics: SB-030 mimics decorin to treat cardiovascular diseases and SB-061 mimics aggrecan...
BioCentury | Jul 11, 2016
Clinical News

SB061: Phase I/II started

...Calif. Product: SB061 , SB-061 Business: Autoimmune Molecular target: NA Description: Mimic of the proteoglycan aggrecan...
Items per page:
1 - 10 of 29